. In this article only the basic principles of the methodology are described.
The isotope dilution approach is used to calculate the rate of release of a given amino acid from endogenous protein. During the intravenous infusion of a strategi¬ cally labeled amino acid (tracer), blood samples are collected to determine the dilution of the tracer by the endogenous amino acid (tracée). When radioactive isotopes are used, this tracer/tracee ratio is defined by the term "specific activity". The flux of the tracée (Ra, reflects their rate of release from endogenous protein, as supported by the fact that the rates of appearance of essential amino acids are proportional to their content in muscle protein (5) . Among the essential amino acids. Ieucine is most commonly used to estimate whole-body protein kinetics because it offers several methodological advantages (4, 5) . A most important fact is that Ieucine, through a reversible transamination reaction, is in equilibrium with its ketoacid (KIC, a-ketoisocaproate). Because this reaction takes place only intracellularly, plasma KIC SA, during the infusion of labelled Ieucine, allows a close estimate ofthe intracellular Ieucine SA (4, 5) . Considering that protein metabolism ( (10) .
The mechanisms through which insulin deficiency reduces muscle or lean body mass in humans have only recently been elucidated. By infusing labeled leucine, several groups of investigators (11) (12) (13) (14) (15) (16) (17) (18) compared the effects of insulin deficiency and treatment on the rates of protein breakdown, synthesis and amino acid oxidation in type 1 diabetic subjects ( Table 2 ). The results of these studies (11) (12) (13) (14) (15) (16) (17) (18) (16) . The resultant greater amino acid availability stimulates amino acid oxidation (11) (12) (13) (14) (15) (16) (17) (18) and, as found in some studies (11, (14) (15) (16) 18) , whole-body protein synthesis. However, the increment of protein synthesis, even when detectable (11, 14- (104) . Hypercortisolism was associated with reduced rates of whole-body protein breakdown and synthesis, whereas amino acid oxidation was similar before and after treatment (104) . Thus (109) or to an increased rate of proteolysis (110) (110) .
Interestingly, in experimental hyperthyroidism, the catabolic effect of thyroid hormones appears to be mitigated by the development of a greater sensitivity to the anti-proteolytic action of insulin (110) . The different conclusions deriving from clinical and experimental hyperthyroidism, in analogy to those discussed pre¬ viously between clinical and experimental hypercortisolism, could be explained partially by the fact that the studies exploring hyperthyroid patients underestimated the rates of whole-body proteolysis because LBM in these patients was not determined. It is also possible that in the course of disease the elevated production thyroid hormones initially induces protein catabolism by increasing whole-body proteolysis and, later, once LBM has been depleted, by primarily reducing wholebody and muscle protein synthesis.
The data on the role played by normal thyroid hormone concentration in the physiological regulation of everyday protein metabolism in normal humans are very limited. In growing rats it has been suggested that thyroid hormones contribute to the increase in protein synthesis induced by meal absorption (113). This does not appear to be the case in humans, according to the evidence that meal-induced changes in protein kinetics occur in the absence of significant changes in the plasma concentrations of T3 and T4 (114) . Indirect information on the potential physiological role played by thyroid hormones can be extrapolated from the studies performed in humans with hypothyroidism. Classical studies published more than 40 years ago have shown that in patients with hypothyroidism the rates of whole-body protein degradation and synthesis are decreased and the protein kinetics are corrected upon replacement of thyroid hormones (115, 116) . These conclusions have been confirmed more recently using labeled leucine to estimate whole-body protein turnover (109 (74) . For this reason and for their recognized gluco-counterregulatory effects (6) (7) (8) (9) , these hormones are jointly considered as "catabolic hormones" despite some of them having proved to be anabolic (see Table 3 
